Opt 6.02(4)
(4) "100 hours of approved study" means a course of study offered on or after January 1, 1987 by an institution approved by the board in accordance with s.
449.18, Stats.
Opt 6.02(6)
(6) "TPA" or "therapeutic pharmaceutical agent" has the meaning given under
s. SPS 10.01.
Opt 6.02 History
History: Cr.
Register, December, 1990, No. 420, eff. 1-1-91; r. (3),
Register, September, 1997, No. 501, eff. 10-1-97:
CR 05-036: cr. (intro.) and (3)
Register January 2006 No. 601, eff. 2-1-06;
CR 06-116: renum. (1) to be (1m), cr. (1), r. (2) and (5), r. and recr. (3) and am. (6),
Register May 2007 No. 617, eff. 6-1-07;
correction in (1), (1m), (3), (6) made under s.
13.92 (4) (b) 7., Stats.,
Register November 2011 No. 671.
Opt 6.03
Opt 6.03
Use of diagnostic pharmaceutical agents. Opt 6.03(1)(1)
Applicability. An optometrist may use topical ocular diagnostic pharmaceutical agents only if the optometrist establishes an adverse reaction plan, as provided under
sub. (3), and if one of the following applies:
Opt 6.03(1)(a)
(a) The board initially issues a license to practice optometry to the optometrist on or after August 1, 2006.
Opt 6.03(1)(b)
(b) The department issued a certificate to the optometrist under s.
449.17, 2003 Stats.
Opt 6.03(1)(c)
(c) The board issues a certificate under
sub. (2) to an optometrist issued a license to practice optometry before August 1, 2006.
Opt 6.03(2)(a)(a) The board shall certify an optometrist to use topical ocular diagnostic pharmaceutical agents if the optometrist was issued a license to practice optometry before August 1, 2006, and the optometrist satisfies the education requirements under
par. (b) and successfully completes the examination required under
par. (c).
Opt 6.03(2)(b)
(b) In addition to the requirements under
par. (c), the board may issue certificates under
par. (a) only to optometrists who successfully complete 60 classroom hours of study in general and ocular pharmacology as it relates to optometry with particular emphasis on the use of topical ocular diagnostic pharmaceutical agents. At least 30 of the 60 classroom hours of study shall be in ocular pharmacology and shall emphasize the systemic effects of and reactions to pharmaceutical agents, including the treatment of any adverse reactions that may occur. The course of study shall be offered by an institution approved by the board and accredited by a regional or professional accrediting organization which is recognized by the Council for Higher Education Accreditation or its successor or the federal department of education, and shall be completed prior to entering the examination required under
par. (c).
Opt 6.03(2)(c)
(c) The board may issue certificates under
par. (a) only to optometrists who successfully complete an examination approved or conducted by the board on the subject of general and ocular pharmacology as it relates to optometry with particular emphasis on the use of topical ocular diagnostic pharmaceutical agents, including the treatment of adverse reactions to such pharmaceutical agents. The examination shall be prepared or approved by the board. The board shall periodically review the validity, reliability, and appropriateness of the examination. The board may do any of the following:
Opt 6.03(2)(c)2.
2. Approve in whole or in part an examination prepared, administered, and graded by the national board of examiners in optometry or another examination provider approved by the board.
Opt 6.03(2)(c)3.
3. Approve and administer an examination prepared and graded by or under the direction of the national board of examiners in optometry or another examination provider approved by the board.
Opt 6.03(2)(d)
(d) No fee may be charged for a certificate issued under this subsection. A certificate issued under this subsection or s.
449.17, 2003 Stats., remains in effect while the optometrist's license to practice optometry remains in effect unless the certificate is suspended or revoked by the board.
Opt 6.03(3)
(3) Adverse reaction plan. Topical ocular diagnostic pharmaceutical agents may be used only by optometrists who have established a plan for the referral of patients who experience adverse reactions from the application of those agents to appropriate medical services.
Opt 6.03(4)
(4) Use of diagnostic pharmaceutical agents. An optometrist who is allowed under
sub. (1) to use diagnostic pharmaceutical agents may not use any pharmaceutical agent that he or she is prohibited from using under
ch. SPS 10.
Opt 6.03 History
History: Cr.
Register, December, 1990, No. 420, eff. 1-1-91; am. (1) (a) and (b),
Register, September, 1997, No. 501, eff. 10-1-97;
CR 06-116: r. and recr.
Register May 2007 No. 617, eff. 6-1-07; correction in (4) made under s.
13.92 (4) (b) 7., Stats.,
Register November 2011 No. 671.
Opt 6.04
Opt 6.04
Use of therapeutic pharmaceutical agents and removal of foreign bodies from eyes. Opt 6.04(1)
(1)
Applicability. No optometrist may use therapeutic pharmaceutical agents or remove foreign bodies from an eye or from an appendage to the eye unless one of the following applies:
Opt 6.04(1)(a)
(a) The board initially issues a license to practice optometry to the optometrist on or after August 1, 2006.
Opt 6.04(1)(c)
(c) The board issues a certificate under
sub. (2) to an optometrist issued a license to practice optometry before August 1, 2006.
Opt 6.04(2)(a)(a) The board shall certify an optometrist to use therapeutic pharmaceutical agents and remove foreign bodies from an eye or from an appendage to the eye if the optometrist was issued a license to practice optometry before August 1, 2006, and the optometrist satisfies all of the following:
Opt 6.04(2)(a)2.
2. The optometrist has successfully completed 100 hours of approved study in the use of therapeutic pharmaceutical agents and the removal of superficial foreign bodies from an eye or from an appendage to the eye. The course of study shall be offered by an institution approved by the board and accredited by a regional or professional accrediting organization that is recognized by the Council for Higher Education Accreditation or its successor or the federal department of education.
Opt 6.04(2)(a)3.
3. The optometrist has passed an examination conducted or approved by the board. The board shall periodically review the validity, reliability, and appropriateness of the examination that it conducts or approves under this subdivision.
Opt 6.04(2)(b)
(b) No fee may be charged for the issuance of a certificate under
par. (a).
Opt 6.04(2)(c)
(c) A certificate issued under
par. (a) or s.
449.18, 2003 Stats., remains in effect while the optometrist's license to practice optometry remains in effect unless the certificate is suspended or revoked by the board.
Opt 6.04(3)
(3) Removals from eyes. An optometrist who is allowed under
sub. (1) to remove a foreign body from an eye or from an appendage to the eye may not remove a foreign body from an eye or from an appendage to the eye if the foreign body is deeper than Bowman's layer of the cornea or deeper than the conjunctiva.
Opt 6.04(4)
(4) Use of therapeutic pharmaceutical agents. Opt 6.04(4)(a)(a) An optometrist who is allowed under
sub. (1) to use therapeutic pharmaceutical agents may not do any of the following:
Opt 6.04(4)(a)1.
1. Prescribe or administer any therapeutic pharmaceutical agent that he or she is prohibited from prescribing or administering under
ch. SPS 10.
Opt 6.04(4)(a)2.
2. Dispense, as defined in s.
450.01 (7), Stats., other than by prescribing or administering. This subdivision does not prohibit the optometrist from providing a complimentary sample of a therapeutic pharmaceutical agent to a patient to whom the optometrist has rendered therapeutic care.
Opt 6.04(4)(b)
(b) An optometrist who is allowed under
sub. (1) to use therapeutic pharmaceutical agents shall include with each prescription order all of the following:
Opt 6.04(4)(b)1.
1. A statement that he or she is allowed under
sub. (1) to use therapeutic pharmaceutical agents.
Opt 6.04(4)(b)2.
2. The indicated use of the therapeutic pharmaceutical agent so prescribed.
Opt 6.04 History
History: Cr.
Register, December, 1990, No. 420, eff. 1-1-91; am. (2), (4) and (5),
Register, January, 1993, No. 445, eff. 2-1-93; renum. (1) to be (1) (a) and am., cr. (1) (b),
Register, April, 1994, No. 460, eff. 5-1-94; am. (1) (a),
Register, April, 1996, No. 484, eff. 5-1-96; renum. (1) (a) to be (1) and am., r. (1) (b), am. (2) to (5),
Register, September, 1997, No. 501, eff. 10-1-97:
CR 05-036: am. (1), renum. (2) to be (2m), cr. (2), (6) and (7)
Register January 2006 No. 601, eff. 2-1-06;
CR 06-116: r. and recr.
Register May 2007 No. 617, eff. 6-1-07; correction in (4) (a) 1. made under s.
13.92 (4) (b) 7., Stats.,
Register November 2011 No. 671.
